This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix reports $63 million net loss for 2017

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix reported a net loss of $13.1 million, or $0.44 per share, in the fourth quarter of 2017 compared with a net loss of $12.8 million, or $0.52 per share, in the fourth quarter of 2016, the company announced in a press release.

The company reported a $63.4 million net loss, or $2.20 per share, for the full year compared with a net loss of $44.7 million, or $1.80 per share, for 2016.

Product sales of ReSure sealant and partner collaborations generated $0.5 million in revenue for the fourth quarter of 2017 and $1.9 million for the entire year, nearly unchanged from 2016.

Total costs and operating expenses for the fourth quarter were $13.2 million compared with $12.9 million for the fourth quarter of 2016. For 2017, total costs were $63.8 million compared with $45.2 million for 2016.

The company reported cash, cash equivalents and marketable securities of $41.5 million as of Dec. 31.